Dapagliflozin-13C6
Dapagliflozin-13C6 (BMS-512148-13C6) is 13C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine[1]. Dapagliflozin induces HIF1 expression and attenuates renal IR injury[2].
Product Specifications
Product Name Alternative
BMS-512148-13C6
UNSPSC
12352005
Target
Isotope-Labeled Compounds
Related Pathways
Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Cancer
Smiles
O[C@@H]1[C@@H](C2=CC(C[13C]3=[13C]([H])[13C]([H])=[13C]([13C]([H])=[13C]3[H])OCC)=C(C=C2)Cl)O[C@H]([C@@H]([C@H]1O)O)CO
Molecular Formula
C1513C6H25ClO6
Molecular Weight
414.83
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Mucin 1 / EMA / Episialin / CD227 (VU-2G7), CF647 conjugate, 0.1mg/mL
CD35 / CR1 (E11), CF568 conjugate, 0.1mg/mL
